Roche Holding AG said a multiple sclerosis drug showed it could work for most forms of the disease in two late-stage trials, ...

Multiple sclerosis (MS) is one of the most common autoimmune diseases affecting the brain and spinal cord, with 2.9 million ...

Multiple sclerosis (MS) is one of the most common autoimmune diseases affecting the brain and spinal cord, with 2.9 million ...

Aging and shifting hormone levels influence how MS changes over time, and the overlap of these factors during midlife can ...

After her MS diagnosis, Becky was worried her kids would have to care for her, but a stem cell transplant has changed the ...

About 1 million people in the U.S. live with multiple sclerosis, a chronic autoimmune disease that inflames the nervous ...

Myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) is a rare autoimmune condition in which the body's ...

After 30 years of living with Multiple Sclerosis (MS), country music star Clay Walker shared that the disease has recently ...

Roche has reported wins for its BTK inhibitor fenebrutinib in a pair of phase 3 studies across two multiple sclerosis (MS) populations. One victory was based on the finding that the candidate was ...

About 1 million people in the U.S. live with multiple sclerosis, a chronic autoimmune disease that inflames the nervous ...

Fenebrutinib shows promise as the first BTK inhibitor for both RMS and PPMS, reducing relapses and slowing disability progression. The FENhance 2 study demonstrated fenebrutinib's efficacy over ...

Discover how wearable technology is changing the understanding of MS through real-time brain function tracking and analysis ...